Semaglutide
Semaglutide
Description
Semaglutide is a synthetic polypeptide that mimics the action of the naturally occurring hormone GLP-1, playing a crucial role in metabolic regulation. It is utilized in managing both type 2 diabetes and obesity.
Overview
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone vital for metabolic function. It is designed to resist degradation by the dipeptidyl peptidase-IV enzyme, providing an extended duration of action compared to native GLP-1. This stability allows for once-weekly administration. Initially approved for the treatment of type 2 diabetes due to its hypoglycemic properties, semaglutide has expanded its clinical indications to include chronic weight management in obese and overweight individuals, even those without diabetes. Its effectiveness stems from its ability to improve glycemic control by stimulating insulin secretion and reducing glucagon, as well as by regulating appetite through central and peripheral mechanisms. Studies have also highlighted its role in mitigating cardiovascular risks in patients with type 2 diabetes. Beyond its current approvals, research continues to explore additional therapeutic applications for semaglutide. Emerging evidence suggests potential benefits in conditions such as nonalcoholic steatohepatitis (NASH) by influencing lipid metabolism and inflammatory responses. Furthermore, investigations into its neuroprotective capabilities and impact on kidney health in diabetic patients are ongoing, pointing to a broader therapeutic potential for this peptide.
Mechanism of Action
Semaglutide acts as a GLP-1 receptor agonist, enhancing glucose-dependent insulin secretion and suppressing glucagon release. This mechanism leads to reduced blood glucose levels, slowed gastric emptying, and increased satiety, which collectively contribute to its therapeutic effects on diabetes and obesity.
Benefits
- •Improves glycemic control
- •Contributes to weight loss
- •Reduces cardiovascular risk in T2D patients
- •Potential neuroprotective effects
- •May improve kidney function in T2D
- •Investigated for NASH treatment
Dosing Notes
Starting doses typically begin at 0.25 mg once weekly, with gradual escalation over several weeks to a maximum of 2.4 mg once weekly, depending on individual tolerance and therapeutic response. This titration helps to minimize gastrointestinal side effects. It is administered via subcutaneous injection.
Reported Side Effects
- •Nausea
- •Vomiting
- •Diarrhea
- •Constipation
- •Abdominal pain
- •Indigestion
- •Injection site reactions (for SQ administration)
- •Hypoglycemia (especially with co-administration of other antidiabetics)
- •Pancreatitis (rare)
- •Thyroid C-cell tumors (observed in rodent studies)
- •Gallbladder disease
- •Diabetic retinopathy complications (rare)
- •Kidney injury (rare)
- •Hypersensitivity reactions (rare)
Safety Notes
Semaglutide has a generally favorable safety profile, but caution is advised for individuals with a history of pancreatitis, thyroid C-cell tumors (specifically Multiple Endocrine Neoplasia syndrome type 2), or diabetic retinopathy. It may affect the absorption of orally administered medications due to slowed gastric emptying. Close monitoring is recommended when co-administered with other antidiabetic therapies due to an increased risk of hypoglycemia.